Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 25, No 18S (June 20 Supplement), 2007: 507
© 2007 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Russu, V. Articles by Tulusan, A. Search for Related Content PubMed Articles by Russu, V. Articles by Tulusan, A.

Abstract

MRI of the breast before and after primary systemic therapy correlates with histopathological tumor size in patients with locally advanced breast cancer (LABC)

Breast Center, Bayreuth, Germany

507

Background: Primary systemic therapy (PST) is a widely accepted preoperative treatment for patients with locally advanced breast cancer (LABC). Different authors beside our study-group showed that MRI is a sensitive method in describing the remaining size of an invasive breast lesion after PST. The established methods for measuring the size of lesions and monitoring the tumour-response to chemotherapy are clinical palpation, mammography and ultrasound, but specificity of these methods is unsatisfactory. Our prospective data is to clarify the accuracy of MRI in monitoring the tumour-response to PST is presented. Methods: 207 female patients (range of age: 26a- 78a) with LABC (cT2 â" cT4) were examined with dynamic contrast enhanced MRI after PST. 173 (84%) patients have had MRI examination before and after PST. 145 (70%) patients had a ductal-invasive, 48 (23%) patients a lobular-invasive carcinoma. 70 (34%) patients were treated with sequential anthracyclin- and taxan-based chemotherapy and 137(66%) with only anthracyclin based chemotherapy. 51% patients were premenopausal. 70% had an ER-positive tumour. The measure of tumour-response to PST was graded in partial response (PR: >50% of tumour reduction mm²), no change (NC: <50%) and complete response (CR: no evidence of residual tumour-cells). Results: Comparing tumour-size measured by MRI before and after PST 119 (69 %) of the patients had PR and 25 (14.5%) CR. The histological tumour- size after PST strongly correlated with the size measured by MRI r = 0,758 (pâ¹ 0.001). Analyzing the tumour-types ductal-invasive carcinomas were significant (p<0.001) better to monitor than lobular-invasive types (r=0.824/r=0.210). Conclusions: preoperative MRI seems to be a helpful tool in estimating the efficacy of the tumour-response to chemotherapy and for the operative planning in the patients with LABC after PST, especially for ductal-invasive tumours.

No significant financial relationships to disclose.

Abstract presentation from the 2007 ASCO Annual Meeting